Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Nektar Therapeutics ( (NKTR) ).
On December 16, 2025, Nektar Therapeutics announced the topline results from the 36-week induction treatment period of its Phase 2b REZOLVE-AA trial for the treatment of severe-to-very-severe alopecia areata. The trial demonstrated that both doses of rezpegaldesleukin more than doubled the reduction in the Severity of Alopecia Tool (SALT) score compared to placebo, with the primary endpoint narrowly missing statistical significance. However, when excluding four patients with major eligibility violations, the treatment achieved statistical significance. The study showed a favorable safety profile, with most adverse events being mild-to-moderate and self-resolving. These results establish a proof-of-concept for rezpegaldesleukin and support its advancement to Phase 3 development.
The most recent analyst rating on (NKTR) stock is a Hold with a $58.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.
Spark’s Take on NKTR Stock
According to Spark, TipRanks’ AI Analyst, NKTR is a Neutral.
Nektar Therapeutics’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue and high leverage. However, the positive outlook from recent clinical trial results and a strong cash position provide some optimism. Technical indicators and valuation metrics are mixed, reflecting uncertainty in the stock’s near-term performance.
To see Spark’s full report on NKTR stock, click here.
More about Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing novel immunology therapies. The company is engaged in the development of investigational drugs, such as rezpegaldesleukin, which is a first-in-class IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, aimed at treating inflammatory skin diseases like alopecia areata.
Average Trading Volume: 829,528
Technical Sentiment Signal: Buy
Current Market Cap: $1.11B
Find detailed analytics on NKTR stock on TipRanks’ Stock Analysis page.